Molgramostim-containing regimen vs G-CSF alone:• Lower 100-day transplant-related mortality (8.8% GM-CSF alone, 8.7% GM-CSF + G-CSF vs 21.7% G-CSF, p=0.034)• Lower 100-day cumulative mortality (10.3% GM-CSF alone vs 24.6% G-CSF, p=0.037)• Lower 600-day invasive fungal disease mortality (1.47% GM-CSF alone, GM-CSF+G-CSF 1.45% vs 11.59%, p=0.016)• Lower infection-related mortality rate (1.47% GM-CSF alone vs 14.49% G-CSF alone, p=0.011). Here, CSF2 is linked to infection.